Mastectomy for ER Positive Breast Cancer: 141 Real Stories

141 stories match breast cancer, ER positive and mastectomy. 92 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Breast CancerBreast Cancer

Primary breast angiosarcoma: R0 resection, disease-free at 6 months

Patient Info: Anonymized, Female, Under 40

Biomarkers: ERG-positive; Ki-67 50%

Disease-free 6 months after skin-sparing mastectomy with R0 resection for localized primary breast angiosarcoma; continued close 3-month surveillance after declining further treatment.

PubMed Central
OutcomeCancer-Free / NED
Kim, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Kim's Survivor Story

Patient Info: Kim, Female

Biomarkers: ER 99% positive; PR 85% positive; HER2-negative

Kim’s ER-positive, PR-positive, HER2-negative ILC responded strongly to Zoladex and Letrozole before skin-sparing mastectomy, with 90% tumor necrosis, clear margins, no lymph node spread, and confirmation that she was cancer-free.

Lobular Breast Cancer Alliance
OutcomeCancer-Free / NED
Allison, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Allison's Patient Story

Patient Info: Allison Tierney, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; CHEK2 mutation; BRCA1/2 negative

As of March 2024, Allison had completed Taxol and Herceptin treatment, was on tamoxifen planned for 10 years, and had moved to 6-month oncology follow-up. No metastatic disease or recurrence was reported.

YouTube — The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Male Invasive Lobular Breast Cancer With a Pathogenic PALB2 Variant

Patient Info: Anonymized, male, 40s

Biomarkers: ER-positive; PR-positive; HER2 not amplified; pathogenic PALB2 variant

He was disease-free at 1-year follow-up after mastectomy, chemotherapy, and radiotherapy.

PubMed Central
OutcomeCancer-Free / NED
Sally, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Sally's Survivor Story

Patient Info: Sally Johnston, 70+

Biomarkers: Estrogen receptor-positive

Sally was in remission by the end of 2014 and remained active about 10 years after treatment.

Dana-Farber
OutcomeCancer-Free / NED
A patient, who was diagnosed with Breast CancerBreast Cancer

Aggressive breast cancer presenting with severe skin infection

Patient Info: Anonymized, Female

Biomarkers: ER 99% positive; PR 99% positive; HER2 1+ / negative; Ki-67 3%; grade 2; 3 interpectoral lymph nodes negative; later axillary-node biopsy benign

She recovered from sepsis and surgery, had no distant metastases and a benign axillary-node biopsy, and was receiving adjuvant radiation with anastrozole ongoing.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage I Breast CancerBreast Cancer

A Breast Cancer Survivor Later Diagnosed With a Separate Metastatic Cancer Affecting Both Retinas

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive, PR-positive, HER2-negative

Her last breast-cancer follow-up showed no evidence of disease after 5 years of endocrine therapy. She later developed a separate widely metastatic cancer favored to be gastrointestinal or pancreaticobiliary in origin and died after choosing hospice.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Metastatic invasive lobular breast carcinoma to pancreas: biliary stent and paclitaxel

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary breast tumor was triple-negative. Pancreatic metastasis was ER-positive/GATA-positive

Metastatic Site: pancreas; coelio-mesenteric lymph nodes

After 21 years of remission, she developed pancreatic and coelio-mesenteric nodal metastases from invasive lobular breast carcinoma; palliative paclitaxel was stopped after 2 courses because her condition deteriorated, and she was lost to follow-up.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

BRCA2-Positive Breast Cancer in a Woman With Down Syndrome

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-negative, germline BRCA2 pathogenic variant

Metastatic Site: lungs, bones

The cancer later progressed with lung and bone metastases and extensive cancer spread through lymphatic vessels in both lungs. She died 59 months after breast surgery.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Male Breast Cancer Controlled for Years Through Multiple Lines of Targeted and Endocrine Therapy

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: Initial tumor ER-positive, PR-positive, HER2-positive; later ER-positive, PR-negative, HER2-negative; PIK3CA mutation; germline BRCA1/2 negative

Metastatic Site: bones, pleura, liver

After a 5-year and 6-month disease-free interval, the cancer recurred in bone and later progressed to the pleura and liver. He died in January 2021, more than 13 years after his 2007 breast-cancer diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Male breast cancer in both breasts linked to Klinefelter syndrome, initially missed

Patient Info: Anonymized, Male | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; Klinefelter syndrome

Metastatic Site: spine / bone

With advanced metastatic disease and an estimated prognosis of weeks or less, care focused on symptom relief under the palliative-care team.

PubMed Central
OutcomeEnd of Life / Hospice
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage III Breast Cancer Linked to Paraneoplastic Neuromyelitis Optica

Patient Info: Anonymized, female, 50s | Stage III

Biomarkers: ER-positive, PR-positive, HER2-negative; tumor AQP4 expression

A 51-year-old woman with Stage III hormone-receptor-positive breast cancer developed a rare paraneoplastic neurologic disorder that caused severe vomiting and spinal-cord symptoms.

PubMed Central
OutcomeNot reported
Susan, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Susan's Survivor Story

Patient Info: Susan, Female, 70+

Biomarkers: 2021 breast cancer described as estrogen-positive and progesterone-positive; HER2 not reported. First breast cancer biomarker status not reported.

As of August 2023, Susan was living in survivorship after a first breast cancer treated with lumpectomy, chemotherapy, and radiation and a later separate breast cancer treated with bilateral mastectomy.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Abigail, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Abigail's Patient Story

Patient Info: Abigail Myers, female, Under 40 | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: bones, brain

Abigail continued living with Stage IV metastatic breast cancer after about 8 years of multiple treatment lines, including therapy for bone and brain metastases.

Dana-Farber
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Chemotherapy complication: methotrexate absorbed into the bloodstream after spinal injection

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; Oncotype DX Recurrence Score 20

Metastatic Site: leptomeninges / central nervous system; brain

Five months after leptomeningeal carcinomatosis was recognised, she developed a new 2 cm brain lesion and neurological decline. Her family chose supportive care, and she died 10 days after transfer to inpatient hospice.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Breast cancer that spread to the thymus gland

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Oestrogen receptor-positive; progesterone receptor-positive; HER2-negative

Metastatic Site: thymus

She had a good response after 4 cycles of abemaciclib, anastrozole and goserelin and continued endocrine treatment with surveillance of the opposite breast.

PubMed Central
OutcomeResponding Well
Becki, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Becki's Patient Story

Patient Info: Becki, Female, 40s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of 2023, Becki was receiving ongoing treatment for Stage II triple-positive breast cancer after recently completing mastectomy and experiencing chemotherapy-related fatigue, hair loss, and chemo fog.

Our Cancer Stories
OutcomeCare Ongoing
Annette, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

HR-Positive Invasive Ductal Carcinoma: Annette's Patient Story

Patient Info: Annette La Fontaine, Female

Biomarkers: ER-positive; PR-positive; HER2-negative

As of January 2023, Annette was in survivorship after bilateral mastectomy and reconstruction and was taking a daily aromatase inhibitor to reduce recurrence risk while rebuilding body confidence and emotional well-being.

The Patient Story
OutcomeCare Ongoing